Daniel Lochner - 06 Jul 2022 Form 4 Insider Report for Oyster Point Pharma, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 06 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jul 2022, 16:55:28 UTC
Prior SEC filing: 04 Jan 2023
Next SEC filing: 06 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Brandon Fenn, Attorney-in-Fact

Key filing fact

Daniel Lochner filed Form 4 for Oyster Point Pharma, Inc. on 08 Jul 2022.

Key facts

This page summarizes Daniel Lochner's Form 4 filing for Oyster Point Pharma, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2022, 16:55.

Change

Previous filing in this sequence was filed on 04 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OYST transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 06 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of performance stock units (the "PSUs"). Each PSU represents a contingent right to receive one share of Common Stock of the Issuer.

Footnote F2

The PSUs will vest as to (i) 50% on July 6, 2023; and (ii) 50% at such time, if any, beginning on July 6, 2023 and ending on July 6, 2024, the 30 day volume-weighted average stock price reaches $6.00 per share (the "VWAP Vesting Period"), subject to the Reporting Person's continuous service to the Issuer through each such date. For clarity, the applicable thirty (30) consecutive day period must occur entirely during the VWAP Vesting Period and the thirty (30) day volume-weighted average stock price will be measured during any thirty (30) consecutive trading days during such VWAP Vesting Period.